PHR

Phreesia just crossed the line that defines a SaaS story: fiscal 2026 delivered its first-ever GAAP net income ($2.3M vs. a $58.5M loss the prior year) on 14% revenue growth to $468M, while operating cash flow jumped 143% to $78.8M and free cash flow went from $8.3M to $54.4M. Management frames this cleanly in the MD&A — Adjusted EBITDA of $101.5M vs. $36.8M — and the platform now facilitates ~180M patient visits a year, giving the network real scale and embeddedness in provider workflows across access, affordability, and outcomes. At $10.94 the stock trades for just 1.4x sales with net cash (only $2.66M long-term debt against $73.8M cash), and the $54.4M FCF is roughly an 8% yield on the $665M market cap. For a still-growing, now-self-funding healthcare software network, that is a cheap price, not a demanding one — the 273x P/E is a math artifact of a razor-thin first profit, not a valuation signal.

The trajectory is the thesis. Losses have compressed every year — $137M (FY24) → $58.5M (FY25) → +$2.3M (FY26) — and the cash-flow swing confirms this is operating leverage, not a one-off. GAAP operating income is still slightly negative (-$6.6M, -1.4% margin), so the profitability is fragile and largely EBITDA/FCF-driven, but the direction and the balance sheet (equity $337M, liabilities/equity 0.97x) give ample runway. R&D held roughly flat at $121M while revenue grew, showing the spend base is finally maturing against a larger top line.